Program
pemvidutide
Its studies are mostly in Non-alcoholic Fatty Liver Disease · Fatty Liver · Alcoholism, led by Altimmune.
Furthest: phase 3, since Aug 14, 20265 company-led studies, 2 open or runningNext primary completion: Sep 30, 2027 (phase 2)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Altimmune | 52 open or running | phase 3since Aug 14, 2026 | Jul 14, 2021 | Sep 30, 2027phase 2 · NCT07009860 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jul 14, 2021First study: phase 1 study in Non-alcoholic Fatty Liver DiseaseFirst studyNCT04972396 · 40 enrolled · Australia
- Jul 24, 2023Phase 2 study in Non-alcoholic Fatty Liver DiseaseNCT05989711 · 212 enrolled · United States, Australia, Puerto Rico
- May 16, 2025Phase 2 study in AlcoholismNCT06987513 · 100 enrolled · United States
- Jun 5, 2025Phase 2 study in Alcohol-associated Liver DiseaseNCT07009860 · 121 enrolled · United States, Puerto Rico
- Aug 14, 2026Phase 3 study in Metabolic Dysfunction-Associated Steatohepatitis (MASH)Phase 3 reachedNCT07795164 · 1,800 planned · United States
Ahead
- Sep 30, 2027Primary completion: phase 2 study in Alcohol-associated Liver DiseaseNCT07009860
- Dec 2028Primary completion: phase 3 study in Metabolic Dysfunction-Associated Steatohepatitis (MASH)NCT07795164
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 5 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07795164Metabolic Dysfunction-Associated Steatohepatitis (MASH) · United States | 3 | Recruiting | Dec 2028 | 1,800 |
| NCT07009860Alcohol-associated Liver Disease · United States, Puerto Rico | 2 | Active, not recruiting | Sep 30, 2027 | 121 |
| NCT06987513Alcoholism · United States | 2 | Completed | Jul 30, 2026 | 100 |
| NCT05989711Non-alcoholic Fatty Liver Disease · United States, Australia, Puerto Rico | 2 | Completed | Nov 25, 2025 | 212 |
| NCT04972396Non-alcoholic Fatty Liver Disease · Australia | 1 | Completed | May 15, 2022 | 40 |
How it is read
Names in the registry
- “Pemvidutide”, 5 entries
Conditions, from the studies’ own filings
- Non-alcoholic Fatty Liver Disease, 2 studies
- Fatty Liver, 1 study
- Alcoholism, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.